Introduction: Cancer remains a major global health challenge, prompting the continuous search for new therapeutic candidates. Natural compounds and their derivatives, such as dihydrocurcubitacin B—a hydrogenated derivative of cucurbitacin B—have gained interest due to their potential anticancer properties. Objectives: This study aimed to evaluate the predicted antineoplastic activities and toxicity profile of dihydrocurcubitacin B using in silico methodologies, providing insight into its relevance as a candidate for oncology drug development. Methods: The compound was analyzed using PASS Online to predict its biological activities, and GUSAR for acute toxicity in rodents via multiple administration routes. Additionally, DIGEP-Pred was used to estimate gene expression modulation (mRNA and protein levels) and assess potential targets relevant to cancer biology. Results: Dihydrocurcubitacin B demonstrated a high probability of antineoplastic activity (Pa = 0.938), particularly against lung (Pa = 0.833), cervical (Pa = 0.773), and sarcoma (Pa = 0.727) cancers. The compound also showed potential as an apoptosis agonist (Pa = 0.918) and hepatic disorder treatment agent (Pa = 0.856). Despite moderate cytotoxicity predictions (Pa = 0.730), its predicted toxicity levels remained within acceptable ranges: IP LD?? = 214.8 mg/kg (Class 4), IV LD?? = 8.95 mg/kg (Class 3), SC LD?? = 9.27 mg/kg (Class 2), and Oral LD?? = 55.04 mg/kg (Class 3). Gene expression predictions (Pa > 0.7) indicated significant downregulation of cancer-related genes such as CHEK1 and SESN1, and upregulation of FOXO1 and VDR, both involved in tumor suppression. Conclusion: In silico analyses suggest that dihydrocurcubitacin B possesses promising antineoplastic properties and modulates gene expression pathways relevant to cancer, particularly apoptosis and tumor proliferation. These findings warrant further experimental validation and may contribute to the development of novel anticancer therapies.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
